Drug Information

Drug General Information
Drug ID
D0VO0T
Former ID
DNCL003479
Drug Name
Delanzomib
Drug Type
Small molecular drug
Indication Myeloma [ICD9: 203; ICD10:C90] Phase 2 [532908]
Company
Cephalon
Structure
Download
2D MOL

3D MOL
Formula
C21H28BN3O5
Canonical SMILES
B(C(CNC(=O)C(C(C)O)NC(=O)C1=CC=CC(=N1)C2=CC=CC=C2)C(C)C<br />)(O)O
InChI
1S/C21H28BN3O5/c1-13(2)16(22(29)30)12-23-21(28)19(14(3)26)25-20(27)18-11-7-10-17(24-18)15-8-5-4-6-9-15/h4-11,13-14,16,19,26,29-30H,12H2,1-3H3,(H,23,28)(H,25,27)/t14-,16+,19+/m1/s1
InChIKey
PPAJFLNVGDSLAB-ALKREAHSSA-N
PubChem Compound ID
57149540
PubChem Substance ID
136023423, 136367513, 152159572
Target and Pathway
Target(s) Proteasome Target Info Modulator [531739]
References
Ref 532908Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Curr Cancer Drug Targets. 2014;14(6):517-36.
Ref 531739Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int Immunopharmacol. 2012 Jan;12(1):257-70.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.